Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Venrock’s VHCP Management’s Top Picks For 2016

Page 1 of 2

At Insider Monkey, we look at the weighted average returns of the long positions a fund indicates in its 13F filings, in companies with a market cap greater than $1 billion, to estimate the returns of the fund’s stock picks in notable stocks. According to our results, hedge funds that focus exclusively on healthcare stocks or which have a major exposure to this industry have fared the best in 2015. For example, Julian Baker And Felix Baker‘s fund Baker Bros. Advisors has generated a positive return of 67.8% in 2015, while the results for Peter Kolchinsky‘s RA Capital Management show a return of 34.5%. In this article we’ll take a look at another fund that focuses on healthcare stocks – Venrock Healthcare Capital Partners (VHCP). Founded in 2009, VHCP Management is a subsidiary of Venrock Associates, a venture capital firm. The fund is run by Anders Hove and Bong Koh, and invests exclusively in healthcare companies, both public and private. According to its latest 13F filing, the fund’s equity portfolio carried a market value of $165 million and contained 21 positions.

An everyday investor doesn’t have the same resources and capabilities to analyze different publicly-traded companies as hedge funds do. This is why it is a good idea to see what stocks hedge funds like the most and try to imitate some of their bullish moves in an attempt to reap market-beating returns. At Insider Monkey, we analyze the 13F filings of several hundred high-performing hedge funds and use the data to see what stocks they are collectively bullish on. Through extensive research we have determined that the best approach to outperform the broader indices is to follow hedge funds into their top small-cap ideas (see more details here).

Anders Hove And Bong Koh
Anders Hove And Bong Koh
VHCP Management

Anders Hove and Bong Koh have decided to lock in some profits on their investment in Coherus Biosciences Inc (NASDAQ:CHRS) during the fourth quarter. According to its 13F filing, VHCP Management’s holding was reduced by 30% to 611,010 shares valued at a little over $14 million. Although 2015 was a roller-coaster year for Coherus Biosciences Inc (NASDAQ:CHRS) stock, it still ended the year up by 39%. Since then, however, the stock has fallen off the cliff, currently down by 38% year-to-date.

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) is another stock Hove and Koh have decided to cash in on, having dumped 89% of their position during the quarter. As a result, VHCP Management now holds 140,756 shares worth approximately $15.9 million. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) is set to release 2015 fourth quarter financial report on February 29, with analysts expecting revenues of $27.9 million and a loss of $0.30 per share. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) has also been crushed amid the recent market sell-off and has slid by 40% since the start of the year. This is not such a big deal, considering that the stock ended 2015 up by 252%.

Follow Anacor Pharmaceuticals Inc. (NASDAQ:ANAC)
Trade (NASDAQ:ANAC) Now!

VHCP Management’s holding in GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) was unchanged over the fourth quarter, with the fund having reported ownership of 311,853 shares valued at $21.6 million in its latest 13F filing. The same position was worth $28.5 million at the end of the third quarter. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has found itself in hot water recently, being accused of providing investors with misleading financial and business information. In its latest Annual Report, the company said its management “does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” Several law firms have filed lawsuits against the company on behalf of shareholders.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!